ISRCTN15320064进行中（未招募）3 期
Comparing the effectiveness of test and treat approaches with doxycycline or the triple-drug therapy with ivermectin/diethylcarbamazine/albendazole vs ivermectin/albendazole for targeted elimination of lymphatic filariasis in a Phase III clinical trial
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age =5 years
- •2. LF-infected person (CFA positive)
- •3. Able and willing to give informed consent
排除标准
- •Specific exclusion criteria for DOX 100 participants:
- •1. Age <14 years or >70 years
- •2. Body weight <40 kg
- •3. Pregnant or breastfeeding women
- •4. Women of childbearing potential not using an agreed method of contraception (including abstinence; oral contraceptives are not allowed because of interaction with trial drugs)
- •5. Known hepatic or renal dysfunction or disease of the central nervous system (CNS)
- •6. History of alcohol or drug abuse
- •7. History of serious adverse reactions to doxycycline or other tetracyclines
- •8. History of photosensitivity reactions after taking drugs.
- •9. Concomitant medication with antacids containing aluminium, magnesium or sucralfate and not able to discontinue
- •10. Concomitant medication with other antibiotics than doxycycline and not able to discontinue
- •11. Concomitant medication with diuretics, sulfonylurea or coumarin (coumadin)
- •12. Any significant condition other than filariasis (including medical and psychological/psychiatric disorder) which in the opinion of the study investigator might interfere with the conduct of the study
- •Laboratory values that will lead to exclusion:
- •1. Positive urine pregnancy test
- •Specific exclusion criteria for IDA participants:
- •1. Age <18 years and >70 years
- •2. Pregnant or breastfeeding women
- •3. Women of childbearing potential not using an agreed method of contraception (including abstinence; oral contraceptives are not allowed because of interaction with trial drugs)
- •4. Known hepatic or renal dysfunction or disease of the central nervous system (CNS)
- •5. History of alcohol or drug abuse
- •6. History of serious adverse reactions to ivermectin, diethylcarbamazine or albendazole
- •7. Any significant condition other than filariasis (including medical and psychological/psychiatric disorder) that in the opinion of the study investigator might interfere with the conduct of the study
- •Laboratory values that will lead to exclusion:
- •1. Positive urine pregnancy test
- •2. Detection of Onchocerca volvulus MF in skin snips after ivermectin but prior to IDA treatment
- •No exclusion criteria apply to participants from the control group (MDA only)
研究者
相似试验
招募中
不适用
Comparison of treatment effectiveness and evaluation of Comparison of treatment effectiveness and evaluation of cost between surgical and non-surgical treatment for gastroesophageal reflux disease (GERD)cost between surgical and non-surgical treatment for gastroesophageal reflux disease (GERD)KCT0003210Korea University Anam Hospital100
已完成
2 期
The effect of arthromac plus in the treatment of knee arthritisOsteoarthritis.Osteoarthritis, unspecified siteIRCT20190226042854N1Zanjan University of Medical Sciences54
尚未招募
1 期
comparison of two periodontal treatment modality in periodontitisCTRI/2018/11/016391Rajasthan University Of Health Sciences College of Dental Sciences
尚未招募
Unknown
Comparison of therapeutic effect and safety of intranasal fluticasone furoate and fluticasone furoate in patients of Chronic Rhinosinusitis: A Randomized, Open Label, Parallel Group StudyCTRI/2024/04/064979Govt Doon Medical college
已完成
不适用
Effectiveness and safety of JHG002 for chronic temporomandibular joint dysfunctioDiseases of the digestive systemKCT0004437Jaseng Medical Foundation82